Literature DB >> 25828088

β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.

Stefano Rivella1.   

Abstract

β-thalassemias are monogenic disorders characterized by defective synthesis of the β-globin chain, one of the major components of adult hemoglobin. A large number of mutations in the β-globin gene or its regulatory elements have been associated with β-thalassemias. Due to the complexity of the regulation of the β-globin gene and the role of red cells in many physiological processes, patients can manifest a large spectrum of phenotypes, and clinical requirements vary from patient to patient. It is important to consider the major differences in the light of potential novel therapeutics. This review summarizes the main discoveries and mechanisms associated with the synthesis of β-globin and abnormal erythropoiesis, as well as current and novel therapies. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25828088      PMCID: PMC4380714          DOI: 10.3324/haematol.2014.114827

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  170 in total

1.  A deletion of the human beta-globin locus activation region causes a major alteration in chromatin structure and replication across the entire beta-globin locus.

Authors:  W C Forrester; E Epner; M C Driscoll; T Enver; M Brice; T Papayannopoulou; M Groudine
Journal:  Genes Dev       Date:  1990-10       Impact factor: 11.361

2.  Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis.

Authors:  Ke Chen; Jing Liu; Susanne Heck; Joel A Chasis; Xiuli An; Narla Mohandas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-28       Impact factor: 11.205

3.  Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning.

Authors:  S Paul Oh; Chang-Yeol Yeo; Youngjae Lee; Heindrich Schrewe; Malcolm Whitman; En Li
Journal:  Genes Dev       Date:  2002-11-01       Impact factor: 11.361

4.  Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.

Authors:  Emilio Ramos; Piotr Ruchala; Julia B Goodnough; Léon Kautz; Gloria C Preza; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

Review 5.  Stress erythropoiesis: new signals and new stress progenitor cells.

Authors:  Robert F Paulson; Lei Shi; Dai-Chen Wu
Journal:  Curr Opin Hematol       Date:  2011-05       Impact factor: 3.284

6.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

7.  Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Authors:  Raffaella Origa; Renzo Galanello; Tomas Ganz; Nicolina Giagu; Liliana Maccioni; Gavino Faa; Elizabeta Nemeth
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

8.  KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia.

Authors:  Dun Liu; Xinhua Zhang; Lihua Yu; Ren Cai; Xiaoxia Ma; Chengguang Zheng; Yuqiu Zhou; Qiji Liu; Xiaofeng Wei; Li Lin; Tizhen Yan; Jiwei Huang; Narla Mohandas; Xiuli An; Xiangmin Xu
Journal:  Blood       Date:  2014-05-14       Impact factor: 22.113

9.  Position-independent, high-level expression of the human beta-globin gene in transgenic mice.

Authors:  F Grosveld; G B van Assendelft; D R Greaves; G Kollias
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

10.  The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin.

Authors:  Laura Silvestri; Alessia Pagani; Antonella Nai; Ivana De Domenico; Jerry Kaplan; Clara Camaschella
Journal:  Cell Metab       Date:  2008-10-30       Impact factor: 27.287

View more
  34 in total

1.  Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.

Authors:  Carla Casu; Mariam Aghajan; Paraskevi Rea Oikonomidou; Shuling Guo; Brett P Monia; Stefano Rivella
Journal:  Haematologica       Date:  2015-09-24       Impact factor: 9.941

2.  Resolutions for the New Year.

Authors:  Jan Cools
Journal:  Haematologica       Date:  2016-01       Impact factor: 9.941

3.  Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.

Authors:  Carla Casu; Mariateresa Pettinato; Alison Liu; Mariam Aghajan; Vania Lo Presti; Maria Rosa Lidonnici; Kevin A Munoz; Emir O'Hara; Violante Olivari; Simona Maria Di Modica; Sheri Booten; Shuling Guo; Garry Neil; Reem Miari; Nir Shapir; Inbal Zafir-Lavie; Hagit Domev; Giuliana Ferrari; Despina Sitara; Antonella Nai; Stefano Rivella
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

4.  Neomorphic effects of the neonatal anemia (Nan-Eklf) mutation contribute to deficits throughout development.

Authors:  Antanas Planutis; Li Xue; Cecelia D Trainor; Mohan Dangeti; Kevin Gillinder; Miroslawa Siatecka; Danitza Nebor; Luanne L Peters; Andrew C Perkins; James J Bieker
Journal:  Development       Date:  2017-02-01       Impact factor: 6.868

Review 5.  Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.

Authors:  Stefano Rivella
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

6.  Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.

Authors:  Daniel Garcia-Santos; Amel Hamdi; Zuzana Saxova; Carine Fillebeen; Kostas Pantopoulos; Monika Horvathova; Prem Ponka
Journal:  Blood       Date:  2017-11-27       Impact factor: 22.113

7.  Rechallenging to Hydroxycarbamide Post Thalidomide Treatment and Response in a Non Transfusion-Dependent Patient, is it Possible?

Authors:  Paolo Ricchi; Silvia Costantini; Anna Spasiano; Patrizia Cinque; Tiziana Di Matola; Massimiliano Ammirabile; Aldo Filosa
Journal:  Indian J Hematol Blood Transfus       Date:  2019-02-11       Impact factor: 0.900

8.  Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.

Authors:  Vania Manolova; Naja Nyffenegger; Anna Flace; Patrick Altermatt; Ahmet Varol; Cédric Doucerain; Hanna Sundstrom; Franz Dürrenberger
Journal:  J Clin Invest       Date:  2019-12-09       Impact factor: 14.808

Review 9.  New therapeutic targets in transfusion-dependent and -independent thalassemia.

Authors:  M Domenica Cappellini; Irene Motta
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 10.  HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics.

Authors:  Rhoda Elison Hirsch; Nathawut Sibmooh; Suthat Fucharoen; Joel M Friedman
Journal:  Antioxid Redox Signal       Date:  2016-11-28       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.